Page last updated: 2024-12-11

ridogrel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5362391
CHEMBL ID280728
CHEBI ID135542
SCHEMBL ID11709
MeSH IDM0167408

Synonyms (36)

Synonym
ibidel
r-68070
ridogrel (usan/inn)
110140-89-1
D05727
ridogrel ,
DB01207
pentanoic acid, 5-(((3-pyridinyl(3-(trifluoromethyl)phenyl)methylene)amino)oxy)-, (e)-
ridogrelum [inn-latin]
(e)-5-(((alpha-3-pyridyl-m-(trifluoromethyl)benzylidene)amino)oxy)valeric acid
r 68070
CHEBI:135542
CHEMBL280728 ,
L001350
EC-000.2105
5-[(e)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
5-[1-pyridin-3-yl-1-(3-trifluoromethyl-phenyl)-meth-(e)-ylideneaminooxy]-pentanoic acid
bdbm50003795
5-[pyridin-3-yl-(3-trifluoromethyl-phenyl)-methyleneaminooxy]-pentanoic acid
(e)-5-(pyridin-3-yl(3-(trifluoromethyl)phenyl)methyleneaminooxy)pentanoic acid
AKOS015951347
unii-qts5qoo42o
ridogrelum
qts5qoo42o ,
ridogrel [usan:inn:ban]
ridogrel [usan]
(e)-5-(((.alpha.-3-pyridyl-m-(trifluoromethyl)benzylidene)amino)oxy)valeric acid
ridogrel [mi]
ridogrel [inn]
SCHEMBL11709
5-{[(e)-{pyridin-3-yl[3-(trifluoromethyl)phenyl]methylidene}amino]oxy}pentanoic acid
DTXSID90872935
MS-25856
5-[[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypenta noic acid
CS-0017567
HY-A0221

Research Excerpts

Overview

Ridogrel is a dual acting thromboxane synthase inhibitor/TP receptor antagonist. Ridogrel does not influence maternal and fetal hemodynamics and uterine contractility. It shows similar antiplatelet activity in the ewe and the fetal lamb.

ExcerptReferenceRelevance
"Ridogrel is a dual acting thromboxane synthase inhibitor/TP receptor antagonist. "( Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat.
Quest, DW; Wilson, TW, 1998
)
2.13
"Ridogrel is a potent thromboxane synthetase inhibitor which passes the sheep placenta, does not influence maternal and fetal hemodynamics and uterine contractility, and shows similar antiplatelet activity in the ewe and the fetal lamb."( Placental transfer of the thromboxane synthetase inhibitor ridogrel in the late-pregnant ewe.
Schneider, TJ; Struijk, PC; Wallenburg, HC, 1999
)
1.99
"Ridogrel is a selective inhibitor of the TxA2 synthase."( Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis.
Bellens, D; Janssen, PA; Vanden Bossche, H; Willemsens, G, 1992
)
2.45
"Ridogrel is a single molecule that efficiently achieves both inhibitions in human volunteers."( Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.
Arnout, J; Deckmyn, H; Hoet, B; Van Geet, C; Verhaeghe, R; Vermylen, J, 1990
)
2.44

Effects

Ridogrel has no significant effect on the regio- and stereoselective P450-dependent oxidations of testosterone in liver microsomes from unpretreated or from 5-pregnen-3 beta-ol-20-one-16 alpha-carbonitrile-, phenobarbital- or 3-methylcholanthrene-pretreated male and female Sprague-Dawley rats.

ExcerptReferenceRelevance
"Ridogrel has a double mechanism of action: it is a combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker, demonstrated in vitro, as well as in vivo in animals and in man. "( [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile].
Assogna, G; Di Perri, T; Notari, M, 1991
)
2.63
"Ridogrel has no significant effect on the regio- and stereoselective P450-dependent oxidations of testosterone in liver microsomes from unpretreated or from 5-pregnen-3 beta-ol-20-one-16 alpha-carbonitrile-, phenobarbital- or 3-methylcholanthrene-pretreated male and female Sprague-Dawley rats."( Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis.
Bellens, D; Janssen, PA; Vanden Bossche, H; Willemsens, G, 1992
)
2.45
"Ridogrel has a double mechanism of action: it is a combined thromboxane A2 synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker, demonstrated in vitro, as well as in vivo in animals and in man. "( [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile].
Assogna, G; Di Perri, T; Notari, M, 1991
)
2.63

Actions

ExcerptReferenceRelevance
"Ridogrel did not lower systolic blood pressure in Sprague-Dawley rats."( Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat.
Quest, DW; Wilson, TW, 1998
)
1.41

Treatment

Ridogrel significantly prevented deterioration of perfusion by increasing plasma and RBC flow mostly in the distal, ischaemic regions of the flap. Treatment with ridogrel at doses blocking either singly thromboxane A2 (TxA2) synthetase (0.63 mg/kg i.v., -15 min, n = 6) reduces (-74%) or abolishes (-100%) respectively the enhancement by TCP + AA of the ADP-induced thrombus formation.

ExcerptReferenceRelevance
"The ridogrel-treated animals showed reduced blood level of TXB2 and increased levels of 6-keto-PGF1 alpha after fMLP challenge."( Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
Arreto, CD; Bureau, MF; De Clerck, F; Lefort, J; Vargaftig, BB, 1992
)
0.76
"Treatment with ridogrel significantly prevented deterioration of perfusion by increasing plasma and RBC flow mostly in the distal, ischaemic regions of the flap where stasis was evident in the control flaps."( Effect of Ridogrel, a thromboxane receptor blocker and synthesis inhibitor on plasma and red blood cell flow in an arterial skin flap in sheep.
al-Ghussain, NM; Banic, A; Kouris, K; Nazzal, M; Rajacic, N; Thulesius, O, 1991
)
1.02
"Treatment with ridogrel at doses blocking either singly thromboxane A2 (TxA2) synthetase (0.63 mg/kg i.v., -15 min, n = 6) or additionally TxA2/prostaglandin endoperoxide receptors (5 mg/kg i.v., -15 min, n = 6) reduces (-74%) or abolishes (-100%) respectively the enhancement by TCP + AA of the ADP-induced thrombus formation."( Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptors by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries.
Andries, R; Bourgain, RH; De Clerck, F; Decuyper, K,
)
0.69

Compound-Compound Interactions

ExcerptReferenceRelevance
" This study reveals 1) a differential efficacy of TXA2 synthase inhibition, singly or combined with TXA2/prostaglandin endoperoxide receptor antagonism, depending on the extent of the vessel wall lesion triggering thrombosis and the size of the thrombus required to obstruct the vascular lumen and 2) a significant synergism in preventing occlusive thrombosis of extensively damaged coronary arteries between strong TXA2 synthase inhibition and comparatively modest TXA2/prostaglandin endoperoxide receptor antagonism with ridogrel."( Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary ar
De Clerck, F; Hemans, C; Van Ammel, K; Van de Water, A; Vandeplassche, G; Wouters, L; Xhonneux, R, 1991
)
0.44

Bioavailability

ExcerptReferenceRelevance
" The good bioavailability and the long duration of action of some of these compounds was demonstrated using ex vivo measurement of the TxRA activity upon oral administration to guinea pigs."( Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs.
Bhagwat, SS; Boswell, C; Cohen, DS; Contardo, N; Dotson, R; Furness, P; Gude, C; Lee, W; Mathis, J; Zoganas, H, 1992
)
0.28

Dosage Studied

Ridogrel is an antagonist of TxA 2/PGH2 receptors and inhibitor of thromboxane synthetase. Repeated dosing (7 days) with ridogrel (3 to 25 mg/kg/day) had an antihypertensive effect in 12-week-old stroke-prone spontaneously hypertensive rats.

ExcerptRelevanceReference
" Methylene Blue (which blocks production of cGMP by EDRF-NO) and Nw-nitro-L-arginine (which inhibits EDRF-NO synthesis), both shifted 5-HT dose-response curves to the left and completely abolished the differences in sensitivity to the agonist."( Nitric oxide and superoxide anions in vascular reactivity of renovascular hypertensive rats.
Bellver, A; Celentano, MM; de la Riva, IJ; Rosón, MI; Vega, GW, 1995
)
0.29
" The dose-response curve obtained with the 5-HT1 receptor agonist, 5-carboxamidotryptamine (5-CT), was biphasic in arteries with endothelium; removal of the endothelium eliminated the first phase of the contraction."( Endothelial thromboxane production plays a role in the contraction caused by 5-hydroxytryptamine in rat basilar arteries.
Descombes, JJ; Devys, M; Laubie, M; Verbeuren, TJ, 1993
)
0.29
" In contrast, repeated dosing (7 days) with ridogrel (3 to 25 mg/kg/day), had an antihypertensive effect in 12-week-old stroke-prone spontaneously hypertensive rats."( Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat.
Quest, DW; Wilson, TW, 1998
)
0.95
" The therapeutic effects of R68070 against ulcerative colitis were observed in both dosage forms in a dose dependent manner."( Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.
Fujita, T; Muranishi, S; Odoriba, T; Okabe, S; Suzuki, T; Tanaka, C; Terabe, A; Tozaki, H; Yamamoto, A, 1999
)
0.3
" Moreover, effects of ridogrel (RID, an antagonist of TxA 2/PGH2 receptors and inhibitor of thromboxane synthetase) were analysed by cumulative dose-response curves to SER in the presence and in the absence of the NO synthase inhibitor N(omega)-nitro-L-arginine (NOLA)."( Serotonin hypersensitivity in aorta of two kidney-two clip hypertensive rats: calcium contribution and prostanoids-nitric oxide interactions.
Celentano, MM; Damiano, PF; de la Riva, IJ; Puyó, AM; Rosón, MI; Speziale, E; Vega, GW, 2001
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
(trifluoromethyl)benzenesAn organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thromboxane A2 receptor Homo sapiens (human)IC50 (µMol)2.48000.00110.71065.2000AID212272; AID212273; AID212275; AID212291
Thromboxane-A synthase Homo sapiens (human)IC50 (µMol)0.00620.00091.230410.0000AID212099; AID212606; AID212612; AID212626; AID212955; AID213115
Thromboxane-A synthaseRattus norvegicus (Norway rat)IC50 (µMol)0.00600.00400.39231.5000AID212099
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thromboxane A2 receptor Homo sapiens (human)Kd8.00000.01096.10278.2000AID212948
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
smooth muscle contractionThromboxane A2 receptor Homo sapiens (human)
G protein-coupled receptor signaling pathwayThromboxane A2 receptor Homo sapiens (human)
response to nutrientThromboxane A2 receptor Homo sapiens (human)
response to xenobiotic stimulusThromboxane A2 receptor Homo sapiens (human)
positive regulation of blood coagulationThromboxane A2 receptor Homo sapiens (human)
response to testosteroneThromboxane A2 receptor Homo sapiens (human)
thromboxane A2 signaling pathwayThromboxane A2 receptor Homo sapiens (human)
response to ethanolThromboxane A2 receptor Homo sapiens (human)
positive regulation of angiogenesisThromboxane A2 receptor Homo sapiens (human)
positive regulation of smooth muscle contractionThromboxane A2 receptor Homo sapiens (human)
cellular response to lipopolysaccharideThromboxane A2 receptor Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisThromboxane A2 receptor Homo sapiens (human)
inflammatory responseThromboxane A2 receptor Homo sapiens (human)
positive regulation of blood pressureThromboxane A2 receptor Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane A2 receptor Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationThromboxane A2 receptor Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayThromboxane A2 receptor Homo sapiens (human)
prostaglandin biosynthetic processThromboxane-A synthase Homo sapiens (human)
icosanoid metabolic processThromboxane-A synthase Homo sapiens (human)
cyclooxygenase pathwayThromboxane-A synthase Homo sapiens (human)
intracellular chloride ion homeostasisThromboxane-A synthase Homo sapiens (human)
response to ethanolThromboxane-A synthase Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane-A synthase Homo sapiens (human)
response to fatty acidThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
thromboxane A2 receptor activityThromboxane A2 receptor Homo sapiens (human)
guanyl-nucleotide exchange factor activityThromboxane A2 receptor Homo sapiens (human)
protein bindingThromboxane A2 receptor Homo sapiens (human)
monooxygenase activityThromboxane-A synthase Homo sapiens (human)
thromboxane-A synthase activityThromboxane-A synthase Homo sapiens (human)
iron ion bindingThromboxane-A synthase Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygenThromboxane-A synthase Homo sapiens (human)
heme bindingThromboxane-A synthase Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityThromboxane-A synthase Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
acrosomal vesicleThromboxane A2 receptor Homo sapiens (human)
plasma membraneThromboxane A2 receptor Homo sapiens (human)
nuclear speckThromboxane A2 receptor Homo sapiens (human)
plasma membraneThromboxane A2 receptor Homo sapiens (human)
endoplasmic reticulumThromboxane-A synthase Homo sapiens (human)
endoplasmic reticulum membraneThromboxane-A synthase Homo sapiens (human)
cytosolThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID89060In vitro activity expressed as EC50 for inhibition of collagen induced platelet aggregation.1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
AID212099Inhibition test of thromboxane A2 synthetase in human gel-filtered platelets.1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.
AID212275In vitro thromboxane-A2 receptor binding affinity to displace by 50% [3H]-SQ 29548 binding from washed human platelets1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
AID158082Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma.1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.
AID89234In vitro inhibition of U 46619 induced aggregation of human PRP1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids.
AID212612In vitro activity on thromboxane A2 synthase inhibition in gel filtered human platelets.1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
AID212606In vitro inhibition of Thromboxane A2 synthase1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs.
AID92820In vitro inhibition of U 46619 induced aggregation of washed human platelets1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids.
AID213115In vitro for inhibitory activity against thromboxane synthase1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compoun
AID62831In vitro inhibition of U 46619 induced contraction of dog saphenous vein1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids.
AID212955In vitro inhibition of Thromboxane synthase using [14C]arachidonic acid as radioligand1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids.
AID212272Displacement of the high affinity radiolabeled ligand [3H]- SQ-29548 from the PGH-2/TXA-2 receptor in human gel-filtered platelets.1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.
AID60981Evaluated for contraction of dog saphenous vein1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs.
AID212100In vitro inhibition of thromboxane-A2 synthase in rat whole blood during clotting at 37 degrees Centigrade1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
AID212948In vitro for antagonistic activity against thromboxane synthase receptor1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compoun
AID158250Tested in vitro for the umolar concentration required to inhibit U-46,619-induced platelet aggregation in human platelet rich plasma (PRP)1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
AID158080Inhibition of collagen-induced platelet aggregation in human platelet rich plasma1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel.
AID419508Volume of distribution at steady state in human at 100 mg, iv2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set.
AID212273In vitro activity on thromboxane A2 receptor antagonism in gel filtered human platelets.1999Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7
Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
AID77240Inhibition of bronchoconstriction in guinea pigs1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs.
AID80177Ex vivo inhibition of U-46,619-induced aggregation of guinea pig platelets after peroral administration of 10 mg/kg dose at 1 hr time1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs.
AID212626TXA2 synthetase inhibition measured by the inhibition of TXB2 formation by human gel-filtered platelets incubated with [14C]arachidonic acid1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel.
AID159931In vitro inhibition of U 46619 induced aggregation of washed platelets1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs.
AID212291TXA2 receptor antagonism, measured by the displacement of [3H]SQ29,548 from the PGH-2/TXA-2 receptor on human platelets1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel.
AID159930Evaluated in vitro for the inhibition of U 46619 induced aggregation of platelet-rich plasma1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (87)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (6.90)18.7374
1990's71 (81.61)18.2507
2000's9 (10.34)29.6817
2010's0 (0.00)24.3611
2020's1 (1.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.99 (24.57)
Research Supply Index4.62 (2.92)
Research Growth Index5.42 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (11.11%)5.53%
Reviews2 (2.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other78 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]